Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity
DOI:
10.1128/mbio.00930-25
Publication Date:
2025-05-20T13:00:08Z
AUTHORS (22)
ABSTRACT
ABSTRACT Dose-limiting toxicities pose a major barrier to cancer treatment. While preclinical studies show that the gut microbiota influences and is influenced by anticancer drugs, data from patients paired with careful side effect monitoring remains limited. Here, we investigate capecitabine (CAP)-microbiome interactions through longitudinal metagenomic sequencing of stool 56 advanced colorectal patients. CAP significantly altered microbiome, enriching for menaquinol (vitamin K2) biosynthesis genes. Transposon library screens, targeted gene deletions, media supplementation revealed protects Escherichia coli drug toxicity. Stool metabolite levels were associated decreased peripheral sensory neuropathy. Machine learning models trained in this cohort predicted an independent cohort. Taken together, these results suggest treatment-associated increases microbial vitamin serve chemoprotective role bacterial host cells. Further, our findings provide foundation in-depth mechanistic dissection, human intervention studies, extension other treatments. IMPORTANCE Side effects are common during treatment cancer. The trillions microbes found within sensitive but treatment-induced shifts remain poorly understood. We profiled treated carefully monitored effects. observed marked expansion genes producing K2 (menaquinone). Vitamin rescued growth was then used information about develop predictive model toxicity validated These production protect both bacteria cells toxicity, providing new opportunities motivating need better understand how dietary intake micronutrients like influence outcomes.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (74)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....